Biotech Pulse
Biotechs finally have a gust of wind in their sails.
In a space of 2 months, biotechs have gone from recording yearly lows in early October, to recording 2019 highs. The 25% surge has been a result of a relatively less threatening regulatory environment and a strengthening of acquisition and partnership activity.
The earlier articles, Healthcare On The March and 4 RNA Stocks For A Biotech Portfolio, emphasized why healthcare should begin to receive greater weight in portfolios as the risk of an industry restructuring has eased somewhat and a recent healthcare